A potential biomarker for the efficacy of complement inhibitors in myasthenia gravis.
BACKGROUND In acetylcholine receptor (AChR) antibody-positive myasthenia gravis (MG), complement activation is a major mechanism underlying impaired neuromuscular transmission and complement inhibitors are used in clinical practice. In the absence of biomarkers predicting responsiveness to complement inhibitors, this s...